Related news from
Tue, 07 May 2024 20:15:00 +0000	Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday May 14, 2024 in Las Vegas. Kevin Gorman, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the conference.
Tue, 07 May 2024 12:30:00 +0000	Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present key information from its neuroendocrinology pipeline, including baseline characteristics data from its CAHtalyst™ Program of crinecerfont in congenital adrenal hyperplasia (CAH), as well as data from its modified-release hydrocortisone studies in primary adrenal insufficiency and CAH, at the European Congress of Endocrinology 2024 meeting in Sweden, May 11–14.
Mon, 06 May 2024 12:30:00 +0000	Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today renewed its commitment to increasing awareness and advancing care for people living with TD during Tardive Dyskinesia Awareness Week, May 5-11. TD is a persistent, involuntary movement disorder associated with the use of antipsychotic medication that may be necessary to treat individuals living with mental illness, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder.1,5-7
Sat, 04 May 2024 12:00:28 +0000	Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam Nvidia stock along with four other leading stocks are in or near buy areas as the market rally appears to be picking up steam.
Fri, 03 May 2024 17:15:00 +0000	Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024 Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.
Thu, 02 May 2024 12:38:21 +0000	Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations Neurocrine Biosciences ( NASDAQ:NBIX ) First Quarter 2024 Results Key Financial Results Revenue: US$515.3m (up 23% from...
Thu, 02 May 2024 07:01:09 +0000	Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ... INGREZZA drives strong sales while new drug approvals and a solid cash position underscore a promising future.
Thu, 02 May 2024 05:06:16 +0000	Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight Financial Performance and Market Dynamics: A SWOT Analysis of Neurocrine Biosciences Inc
Thu, 02 May 2024 03:36:09 +0000	Q1 2024 Neurocrine Biosciences Inc Earnings Call Q1 2024 Neurocrine Biosciences Inc Earnings Call
Thu, 02 May 2024 01:01:55 +0000	Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements Neurocrine Biosciences Reports Robust Financial Performance and Pipeline Progress
Wed, 01 May 2024 20:18:16 +0000	Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech Neurocrine stock rose Wednesday after the leading biotech topped Wall Street's sales expectations and wrapped a key regulatory filing.
Wed, 01 May 2024 13:30:21 +0000	Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Wed, 01 May 2024 12:15:06 +0000	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates Neurocrine (NBIX) delivered earnings and revenue surprises of -59.62% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Wed, 01 May 2024 11:00:00 +0000	Neurocrine Biosciences Reports First Quarter 2024 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2024 and provided an update on its 2024 financial guidance.
Tue, 30 Apr 2024 21:48:23 +0000	CORRECTED-UPDATE 2-US FDA approves Neurocrine Biosciences' movement disorder drug (April 30) The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the company said on Tuesday. Huntington's disease is an inherited condition that causes the progressive breakdown of nerve cells in the brain, resulting in a gradual decline in motor control, cognition and mental stability. Ingrezza was first approved in 2017 in its oral capsule formulation to treat adults with movement disorder tardive dyskinesia.
Tue, 30 Apr 2024 21:12:00 +0000	Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.1 INGREZZA SPRINKLE provides an alternative administration option for those who experience dysphagia or have difficulty swallowing.
Tue, 30 Apr 2024 13:15:24 +0000	Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics Beyond analysts' top -and-bottom-line estimates for Neurocrine (NBIX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Wed, 24 Apr 2024 14:15:33 +0000	Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands? Top-notch biotech stock Neurocrine surged Tuesday after analysts suggested the company's depression treatment could rival ketamine.
Wed, 24 Apr 2024 14:01:38 +0000	Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wed, 24 Apr 2024 12:30:00 +0000	Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap in the need for helpful information about congenital adrenal hyperplasia (CAH) and acknowledges the frustrations and challenges experienced by the community in managing the condition.